Stringent Hepatic Monitoring Urged For Diabetes Drug Clinical Trials
Executive Summary
Difficulties surrounding the assessment of a possible case of drug-induced liver injury in the dapagliflozin clinical program show why more standardized hepatic monitoring is needed in future studies of type 2 diabetes agents, one of FDA’s outside advisors said.
You may also be interested in...
Dapagliflozin Faces Ominous Prospect Of New Trials
FDA’s rejection of Bristol-Myers Squibb and AstraZeneca’s diabetes drug dapagliflozin may mean new trials are needed, which would be a blow for the drug as well as a bad sign for the new class of SGLT2 inhibitors.
Dapagliflozin’s CV Profile Shines, But FDA Panel Review Falls On Cancer Concerns
The July 19 FDA advisory committee meeting on Bristol-Myers Squibb Co./AstraZeneca PLC's dapagliflozin reflects the hurdles facing type 2 diabetes drug sponsors even when cardiovascular safety concerns are taken out of the picture.
Dapagliflozin’s CV Profile Shines, But FDA Panel Review Falls On Cancer Concerns
The July 19 FDA advisory committee meeting on Bristol-Myers Squibb Co./AstraZeneca PLC's dapagliflozin reflects the hurdles facing type 2 diabetes drug sponsors even when cardiovascular safety concerns are taken out of the picture.